Literature DB >> 3818574

Polymorphonuclear leukocyte-platelet interactions: acetylglyceryl ether phosphocholine-induced platelet activation under stimulation with chemotactic peptide.

M Oda, K Satouchi, K Yasunaga, K Saito.   

Abstract

A mixture of rabbit polymorphonuclear leukocytes (PMNs) and platelets at concentrations of 5 X 10(6) PMN and 3.5 X 10(8) platelets/ml Tyrode's solution was stimulated with the chemotactic peptide, formyl-methionyl-leucyl-phenylalanine (FMLP). A micromolar concentration of FMLP elicited an immediate weak aggregation, followed by a strong aggregation with a time lag of about 1 min. Microscopic examination showed that the immediate aggregation was due to PMNs and the delayed one was more complex and involved platelets. The delayed aggregation was dependent upon the concentrations of both the PMNs and FMLP. The delayed aggregation was completely blocked by pretreatment of the PMN-platelet mixture with 8 microM CV-3988, a specific receptor antagonist of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (AGEPC), or by the application of platelets desensitized to AGEPC. The time course of AGEPC production by PMNs was well matched to that of the biphasic aggregation response. Furthermore, nordihydroguaiaretic acid inhibited both the AGEPC production by PMNs and the delayed aggregation in a similar dose-dependent manner. These result demonstrate that AGEPC, newly-generated by PMNs under FMLP-stimulation, is of primary importance in platelet aggregation in a PMN-platelet mixed system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3818574     DOI: 10.1093/oxfordjournals.jbchem.a121815

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  8 in total

1.  Platelet-activating-factor-mediated pathogenesis in Lyme disease.

Authors:  E Isogai; K Kimura; N Fujii; T Nishikawa; N Ishii; D Postic; G Baranton; H Isogai
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

2.  Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children.

Authors:  M Miwa; T Miyake; T Yamanaka; J Sugatani; Y Suzuki; S Sakata; Y Araki; M Matsumoto
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

Review 3.  Bidirectional modulation of platelet and polymorphonuclear leukocyte activities.

Authors:  A Del Maschio; E Dejana; G Bazzoni
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

4.  Platelet-leukocyte interaction: activation of rabbit platelets by FMLP-stimulated neutrophils.

Authors:  E Coëffier; D Joseph; M C Prévost; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

5.  Platelet-leukocyte interaction in adhesion to endothelial cells induced by platelet-activating factor in vitro.

Authors:  M Hirafuji; H Shinoda
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

6.  Role of platelet-activating factor in aggregation of leukocytes and platelets in cerebral ischemia.

Authors:  S Uchiyama; M Yamazaki; S Maruyama
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

7.  Platelet-activating factor detected in bronchoalveolar lavage fluids from an asthmatic patient.

Authors:  T Horii; H Okazaki; M Kino; Y Kobayashi; K Satouchi; K Saito
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

8.  The formyl peptide fMLF primes platelet activation and augments thrombus formation.

Authors:  Maryam F Salamah; Divyashree Ravishankar; Rajendran Vaiyapuri; Leonardo A Moraes; Ketan Patel; Mauro Perretti; Jonathan M Gibbins; Sakthivel Vaiyapuri
Journal:  J Thromb Haemost       Date:  2019-05-24       Impact factor: 5.824

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.